FZB NeuesLogo 2017 Deutsch

Die Lunge im Fokus
Die Lunge im Fokus
Die Lunge im Fokus
Die Lunge im Fokus
die-lunge-im-fokus-fzb.jpg
Focus on the lungs
We are the lung research center of the Leibniz Association.
Our main focus: Common diseases such as asthma, allergies and chronic obstructive pulmonary disease (COPD), as well as infection-related inflammation of the lungs, in particular tuberculosis (TB).
Our Mission
die-lunge-im-fokus-fzb.jpg
Chronic lung diseases
The program area is dedicated to research into asthma, COPD and allergies, as these are among the most common chronic diseases and therefore cause an enormous burden for both patients and healthcare systems.
Priority Research Area
die-lunge-im-fokus-fzb.jpg
Infections
The Infections program area is dedicated to researching and combating bacterial infectious diseases of the lung with a focus on tuberculosis.
The aim is to improve the control and treatment of this disease.
To the program area
die-lunge-im-fokus-fzb.jpg
Science & Technology
This area combines overarching research units that are essential for research at the FZB and represent an important link between the subject areas.
Further Information
previous arrow
next arrow

News

  • calendar regular01.08.2025

    UNITE4TB flagship trial completes first wave recruitment

    Tuberculosis (TB) is a major threat to public health and is among the leading causes of death worldwide, according to the World Health Organization. The emergence of drug-resistant TB and current standard of long treatment regimens have increased the urgent need for new, more effective therapies. 

  • calendar regular05.08.2025

    Lese-Tipp: 37. Allergie-Kolloquium

    In der aktuellen Ausgabe des Allergo Journals ist eine sehr lesenswerte Zusammenfassung des diesjährigen Allergie-Kolloquiums erschienen, der einen sehr schönen Überblick über die Themenvielfalt dieser traditionsreichen Veranstaltung am Forschungszentrum Borstel, Leibniz Lungenzentrum gibt.

  • calendar regular25.07.2025

    Global trial evaluates shortened treatment for highly drug-resistant tuberculosis

    A major international clinical trial published this week in The Lancet Respiratory Medicine has assessed the efficacy and safety of a novel, shortened treatment regimen for patients with pre-extensively drug-resistant tuberculosis (pre-XDR TB)—a form of tuberculosis that is resistant to both rifampicin and fluoroquinolones. 

Events

  • Lipidomics Forum 2025

    calendar regular14. - 17. September 2025
    location dot solidUniversity Vienna, Institute of Analytical Chemistry, 1090 Vienna, Austria

  • Northern Germany Meeting on Infection, Immunology and Inflammation

    calendar regular08. Oktober 2025
    location dot solidBorstel

  • Antibiotics LC-MS/MS Quantitation - DZIF Online Course

    calendar regular16. Oktober 2025
    location dot solidonline